The label is just one example. Hard to get around one is obtaining more than X percent of a market. If the market is X big and one is now getting X plus that is further evidence of infringement.
The question is do the generics want to roll the dice on a jury trial where damages could be significant. This time around the generics are the ones who stand to lose a lot. The risk reward is asymmetric.
News 
Market Data 
Discover 
AI
